Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 12/20 | 0.40 |
| ▸ | GYS1 | P13807 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13586614 | 0.96 | FFAR4 (0.41) | FFAR4GYS1GRM2FFAR1OPRM1 | |
| SCHEMBL12822641 | 0.92 | FFAR4 (0.43) | FFAR4GYS1FFAR1MAOB | |
| SCHEMBL13654169 | 0.92 | FFAR4 (0.41) | FFAR4GYS1FFAR1OPRM1OPRD1 | |
| SCHEMBL13586619 | 0.88 | FFAR4 (0.44) | FFAR4GYS1FFAR1MAOB | |
| SCHEMBL13654154 | 0.88 | FFAR4 (0.39) | FFAR4GYS1FFAR1OPRM1OPRD1 | |
| SCHEMBL12822850 | 0.85 | FFAR4 (0.37) | FFAR4GYS1FFAR1MAOBNPC1 | |
| SCHEMBL12823287 | 0.85 | FFAR4 (0.37) | FFAR4GYS1FFAR1MAOB | |
| SCHEMBL13586291 | 0.85 | RARB (0.34) | FFAR4GRM2 | |
| SCHEMBL12823408 | 0.85 | FFAR4 (0.37) | FFAR4GYS1FFAR1MAOBNPC1 | |
| SCHEMBL12823794 | 0.85 | FFAR4 (0.37) | FFAR4GYS1FFAR1MAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | FFAR4 546/4885GYS1 4252/4885GRM2 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.